Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cash and prizes boost HIV pill taking in uganda trial

NCT ID NCT05378607

Disease control Sponsor: RAND Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether offering small prizes (phone credit) can encourage young people aged 15-30 with HIV to take their medication every day. 560 participants in Uganda are split into groups with different reward rules. The goal is to see if these low-cost incentives improve adherence and viral suppression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
incentive program (prize drawings for airtime rewards)
What this could lead to
If successful, this could show that simple, low-cost rewards help people stick to their HIV medication, improving health and reducing virus spread.
What could go wrong
This is a behavioral study, not a medical treatment. The effect may be small or not last long, and results may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 560 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * If the participant is between 15 and 30 years of age (inclusive), * has received ART from Mildmay for at least three months, * exhibits Wisepill-measured adherence of under 90%, * and has regular access to a mobile phone (at least five days per week) Exclusion Criteria: * If the participant is not within the age range specified above, * has not received ART from Mildmay for at least three months, * cannot use a Wisepill device when taking ART medication, * cannot follow the consenting procedures * does not have regular access to a mobile phone (at least five days per week) * or shows Wisepill-measured adherence of over 90%

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ART are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arts syndrome Health Behavior HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ART HIV

Contacts and locations

Locations

  • Mildmay Uganda

    Kampala, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.